{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:19:34Z","timestamp":1790399974975,"version":"4.1.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.critrevonc.2022.103882","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:49:15Z","timestamp":1670255355000},"page":"103882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Targeting RET alterations in cancer: Recent progress and future directions"],"prefix":"10.1016","volume":"181","author":[{"given":"Arafat","family":"Shabbir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsenije","family":"Kojadinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabinda","family":"Shafiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhjot S.","family":"Mundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2022.103882_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102179","article-title":"Immunotherapy in non-small cell lung cancer harbouring driver mutations","volume":"96","author":"Addeo","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103882_bib2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mcne.1999.0754","article-title":"GDNF family neurotrophic factor signaling: four masters, one servant?","volume":"13","author":"Airaksinen","year":"1999","journal-title":"Mol. Cell Neurosci."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103882_bib3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.annonc.2020.11.021","article-title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","volume":"32","author":"Belli","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103882_bib4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1089\/thy.2013.0137","article-title":"In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer","volume":"23","author":"Bentzien","year":"2013","journal-title":"Thyroid"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103882_bib5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2217\/imt-2021-0035","article-title":"Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer","volume":"13","author":"Bhandari","year":"2021","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103882_bib6","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","article-title":"FDA approval summary: selpercatinib for the treatment of lung and thyroid cancers with RET gene mutations or fusions","volume":"27","author":"Bradford","year":"2021","journal-title":"Clin. Cancer Res"},{"issue":"9940","key":"10.1016\/j.critrevonc.2022.103882_bib7","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103882_bib8","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2022.103882_bib9","doi-asserted-by":"crossref","first-page":"14628","DOI":"10.1074\/jbc.M110.195461","article-title":"RET modulates cell adhesion via its cleavage by caspase in sympathetic neurons","volume":"286","author":"Cabrera","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"36","key":"10.1016\/j.critrevonc.2022.103882_bib10","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103882_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/jnci\/djj069","article-title":"BAY 43-9006 inhibition of oncogenic RET mutants","volume":"98","author":"Carlomagno","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12943-018-0799-8","article-title":"The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer","volume":"17","author":"Cerrato","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103882_bib13","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.21037\/tlcr-20-346","article-title":"Decade in review: a new era for RET-rearranged lung cancers","volume":"9","author":"Choudhury","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103882_bib14","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1210\/en.2006-0921","article-title":"RET\/PTC rearrangements and BRAF mutations in thyroid tumorigenesis","volume":"148","author":"Ciampi","year":"2007","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103882_bib15","doi-asserted-by":"crossref","first-page":"E342","DOI":"10.1210\/jc.2010-0771","article-title":"RET-mediated cell adhesion and migration require multiple integrin subunits","volume":"95","author":"Cockburn","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.critrevonc.2022.103882_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4137\/CMO.S6197","article-title":"Vandetanib (ZD6474) in the treatment of medullary thyroid cancer","volume":"5","author":"Deshpande","year":"2011","journal-title":"Clin. Med Insights Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103882_bib17","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/annonc\/mdw163","article-title":"Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103882_bib18","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-18-0839","article-title":"A phase I\/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105","volume":"9","author":"Drilon","year":"2019","journal-title":"Cancer Disco"},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103882_bib19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"6585","key":"10.1016\/j.critrevonc.2022.103882_bib20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/381789a0","article-title":"GDNF signalling through the Ret receptor tyrosine kinase","volume":"381","author":"Durbec","year":"1996","journal-title":"Nature"},{"issue":"6461","key":"10.1016\/j.critrevonc.2022.103882_bib21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/367378a0","article-title":"Mutations of the RET proto-oncogene in Hirschsprung's disease","volume":"367","author":"Edery","year":"1994","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.critrevonc.2022.103882_bib22","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103882_bib23","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1242\/dev.128.20.3963","article-title":"RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons","volume":"128","author":"Enomoto","year":"2001","journal-title":"Development"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103882_bib24","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"issue":"269","key":"10.1016\/j.critrevonc.2022.103882_bib25","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103882_bib26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1200\/JCO.2016.70.9352","article-title":"Targeting RET in patients With RET-rearranged lung cancers: results from the global, multicenter RET registry","volume":"35","author":"Gautschi","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103882_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103882_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000799","article-title":"Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies","volume":"5","author":"Hegde","year":"2020","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103882_bib29","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1158\/1535-7163.MCT-16-0258","article-title":"Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma","volume":"15","author":"Huang","year":"2016","journal-title":"Mol. Cancer Ther."},{"issue":"suppl 16","key":"10.1016\/j.critrevonc.2022.103882_bib30","article-title":"Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy","volume":"40","author":"Kalchiem-Dekel OF","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2022.103882_bib31","doi-asserted-by":"crossref","first-page":"14213","DOI":"10.1074\/jbc.M312600200","article-title":"Identification of RET autophosphorylation sites by mass spectrometry","volume":"279","author":"Kawamoto","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103882_bib32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat. Med"},{"issue":"24","key":"10.1016\/j.critrevonc.2022.103882_bib33","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2022.103882_bib34","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103882_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103119","article-title":"Beyond EGFR, ALK and ROS1: current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma","volume":"156","author":"Lamberti","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103882_bib36","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1158\/1078-0432.CCR-16-1887","article-title":"Antitumor activity of RXDX-105 in multiple cancer types with RET rearrangements or mutations","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/ERC-16-0393","article-title":"Differential roles of RET isoforms in medullary and papillary thyroid carcinomas","volume":"24","author":"Lian","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103882_bib38","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103882_bib39","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0168-9525(01)02420-9","article-title":"The RET receptor: function in development and dysfunction in congenital malformation","volume":"17","author":"Manie","year":"2001","journal-title":"Trends Genet."},{"issue":"16_suppl","key":"10.1016\/j.critrevonc.2022.103882_bib40","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1200\/JCO.2022.40.16_suppl.6080","article-title":"Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial","volume":"40","author":"Mansfield","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103882_bib41","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/humu.20928","article-title":"Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype\/phenotype correlations","volume":"30","author":"Margraf","year":"2009","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103882_bib42","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib43","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103882_bib44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrc3680","article-title":"RET revisited: expanding the oncogenic portfolio","volume":"14","author":"Mulligan","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"suppl 16","key":"10.1016\/j.critrevonc.2022.103882_bib45","article-title":"Comparison of TAS0953\/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases","volume":"40","author":"Odintsov IL","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103882_bib46","first-page":"3","article-title":"Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers","author":"Offin","year":"2019","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.critrevonc.2022.103882_bib47","article-title":"RET fusion in the firing line","author":"O'Leary","year":"2021","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0896-6273(01)00188-X","article-title":"Released GFRalpha1 potentiates downstream signaling, neuronal survival, and differentiation via a novel mechanism of recruitment of c-Ret to lipid rafts","volume":"29","author":"Paratcha","year":"2001","journal-title":"Neuron"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103882_bib49","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0092-8674(03)00435-5","article-title":"The neural cell adhesion molecule NCAM is an alternative signaling receptor for GDNF family ligands","volume":"113","author":"Paratcha","year":"2003","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103882_bib50","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1210\/jc.2009-2461","article-title":"Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"95","author":"Robinson","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103882_bib51","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103882_bib52","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157488408784293705","article-title":"The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway","volume":"3","author":"Roodhart","year":"2008","journal-title":"Curr. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/1078-0432.CCR-20-2278","article-title":"Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib","volume":"27","author":"Rosen","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib54","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103882_bib55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3468(00)80031-7","article-title":"Incidence of RET mutations in patients with Hirschsprung's disease","volume":"35","author":"Sancandi","year":"2000","journal-title":"J. Pedia Surg."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103882_bib57","doi-asserted-by":"crossref","first-page":"a009233","DOI":"10.1101\/cshperspect.a009233","article-title":"Central role of RET in thyroid cancer","volume":"5","author":"Santoro","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103882_bib58","first-page":"11","article-title":"RET gene fusions in malignancies of the thyroid and other tissues","author":"Santoro","year":"2020","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103882_bib59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"New Engl. J. Med"},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103882_bib60","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","article-title":"Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma","volume":"28","author":"Schlumberger","year":"2017","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103882_bib61","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2796.1995.tb01206.x","article-title":"RET-deficient mice: an animal model for Hirschsprung's disease and renal agenesis","volume":"238","author":"Schuchardt","year":"1995","journal-title":"J. Intern Med."},{"key":"10.1016\/j.critrevonc.2022.103882_bib62","unstructured":"Selleckchem. FDA-approved & Passed Phase I Drug Library Contents: SelleckChem; [Available from: \u3008https:\/\/www.selleckchem.com\/screening\/fda-approved-passed-phase-i-drug-library.html\u3009."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103882_bib63","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/nrc3612","article-title":"Tyrosine kinase gene rearrangements in epithelial malignancies","volume":"13","author":"Shaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103882_bib64","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib65","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2015.04.004","article-title":"Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases","volume":"89","author":"Subbiah","year":"2015","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103882_bib66","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision Targeted Therapy with BLU-667 for RET-Driven Cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103882_bib67","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2022.103882_bib68","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103882_bib69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2022.103882_bib70","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.9035","article-title":"Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer","volume":"36","author":"Subbiah VC","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"suppl 16","key":"10.1016\/j.critrevonc.2022.103882_bib71","article-title":"Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: a global, multicenter, registrational trial update (LIBRETTO-001)","volume":"40","author":"Subbiah VW","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103882_bib72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103882_bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.drudis.2016.07.010","article-title":"Exploiting receptor tyrosine kinase co-activation for cancer therapy","volume":"22","author":"Tan","year":"2017","journal-title":"Drug Disco Today"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103882_bib74","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1242\/dev.126.12.2785","article-title":"Signalling by the RET receptor tyrosine kinase and its role in the development of the mammalian enteric nervous system","volume":"126","author":"Taraviras","year":"1999","journal-title":"Development"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103882_bib75","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103882_bib76","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00383-015-3731-y","article-title":"RET gene is a major risk factor for Hirschsprung's disease: a meta-analysis","volume":"31","author":"Tomuschat","year":"2015","journal-title":"Pedia Surg. Int."},{"issue":"1\u20132","key":"10.1016\/j.critrevonc.2022.103882_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1006\/mcne.1998.0667","article-title":"Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase","volume":"11","author":"Trupp","year":"1998","journal-title":"Mol. Cell Neurosci."},{"issue":"35","key":"10.1016\/j.critrevonc.2022.103882_bib78","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1200\/JCO.2012.44.1477","article-title":"RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer","volume":"30","author":"Wang","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103882_bib79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1200\/JCO.2009.23.6604","article-title":"Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer","volume":"28","author":"Wells","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103882_bib80","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103882_bib81","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103882_bib82","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"New Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103882_bib83","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822003067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822003067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:46:20Z","timestamp":1760903180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822003067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":83,"alternative-id":["S1040842822003067"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103882","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting RET alterations in cancer: Recent progress and future directions","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103882"}}